Related Experiment Video

Updated: Oct 25, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

724

Bidirectional Relationship between COVID-19 and Diabetes: Role of Renin-Angiotensin-Aldosterone System and Drugs

Razia Khanam1

  • 1Department of Biomedical Sciences, College of Medicine, Gulf Medical University, Ajman, UAE.

Journal of Pharmacy & Bioallied Sciences
|August 5, 2021
PubMed

Insights

The bidirectional relationship between COVID-19 and diabetes is explored, focusing on the renin-angiotensin-aldosterone system (RAAS). This review examines how RAAS and its modulators impact treatment for patients with both conditions.

Area of Science:

  • Endocrinology and Metabolism
  • Infectious Diseases
  • Cardiovascular Physiology

Background:

  • Diabetic patients face increased risk of severe coronavirus disease-2019 (COVID-19).
  • Emerging evidence suggests a bidirectional link: COVID-19 may also induce diabetes.
  • The renin-angiotensin-aldosterone system (RAAS) is implicated in this complex interplay.

Purpose of the Study:

  • To summarize the role and impact of the renin-angiotensin-aldosterone system (RAAS) in the bidirectional association between COVID-19 and diabetes.
  • To discuss the effects of RAAS-modulating drugs on managing patients with both conditions.

Main Methods:

  • Literature review synthesizing existing reports and data.
  • Analysis of proposed mechanisms linking RAAS, COVID-19, and diabetes.
  • Discussion of therapeutic strategies involving RAAS modulators.

Main Results:

  • The renin-angiotensin-aldosterone system (RAAS) plays a significant role in the two-way relationship between COVID-19 and diabetes.
  • Drugs that modulate RAAS can influence the clinical course and treatment outcomes for affected patients.
  • Dysregulation of RAAS is a key factor in the pathophysiology of combined COVID-19 and diabetes.

Conclusions:

  • Understanding RAAS is crucial for managing the dual burden of COVID-19 and diabetes.
  • Targeting RAAS pathways may offer therapeutic benefits in restoring metabolic and physiological balance.
  • Further research is needed to fully elucidate the impact of RAAS modulators in COVID-19-associated diabetes.

Keywords:
Beta receptor antagonistscoronavirusdiabetesrenin–angiotensin–aldosterone system

More Related Videos

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

386
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.1K

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
942
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
600
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.8K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
551
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
34.2K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
1.9K